RCT: Efficacy and safety of ultrahigh-dose Methylcobalamin in early-stage amyotrophic lateral sclerosis.
16 May, 2022 | 02:02h | UTCEfficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial – JAMA Neurology (link to abstract – $ for full-text)
Commentary on Twitter
A phase 3 clinical trial found ultra-high dose methylcobalamin slowed functional decline in patients with early-stage amyotrophic lateral sclerosis. https://t.co/r5KP38JkUc
— JAMA Neurology (@JAMANeuro) May 9, 2022